[go: up one dir, main page]

WO2018169901A8 - Promoteurs synthétiques - Google Patents

Promoteurs synthétiques Download PDF

Info

Publication number
WO2018169901A8
WO2018169901A8 PCT/US2018/022093 US2018022093W WO2018169901A8 WO 2018169901 A8 WO2018169901 A8 WO 2018169901A8 US 2018022093 W US2018022093 W US 2018022093W WO 2018169901 A8 WO2018169901 A8 WO 2018169901A8
Authority
WO
WIPO (PCT)
Prior art keywords
synthetic promoters
cells
cancer cells
diseased
aspects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/022093
Other languages
English (en)
Other versions
WO2018169901A1 (fr
Inventor
Timothy Kuan-Ta Lu
Lior Nissim
Ming-Ru Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Priority to JP2019550749A priority Critical patent/JP2020509772A/ja
Priority to EP18718955.0A priority patent/EP3596221A1/fr
Priority to US16/493,340 priority patent/US11718860B2/en
Priority to CN201880017696.5A priority patent/CN110582574A/zh
Publication of WO2018169901A1 publication Critical patent/WO2018169901A1/fr
Publication of WO2018169901A8 publication Critical patent/WO2018169901A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/04—Uses of viruses as vector in vivo
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Des aspects de la présente invention concernent des promoteurs synthétiques qui sont modulés de manière différentielle entre certaines cellules malades (par exemple, des cellules cancéreuses) et des cellules normales (par exemple, des cellules non cancéreuses). Ces promoteurs synthétiques sont utiles, par exemple, pour l'expression ciblée de molécules thérapeutiques dans des cellules malades.
PCT/US2018/022093 2017-03-13 2018-03-13 Promoteurs synthétiques Ceased WO2018169901A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2019550749A JP2020509772A (ja) 2017-03-13 2018-03-13 合成プロモーター
EP18718955.0A EP3596221A1 (fr) 2017-03-13 2018-03-13 Promoteurs synthétiques
US16/493,340 US11718860B2 (en) 2017-03-13 2018-03-13 Synthetic promoters
CN201880017696.5A CN110582574A (zh) 2017-03-13 2018-03-13 合成启动子

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762470754P 2017-03-13 2017-03-13
US62/470,754 2017-03-13

Publications (2)

Publication Number Publication Date
WO2018169901A1 WO2018169901A1 (fr) 2018-09-20
WO2018169901A8 true WO2018169901A8 (fr) 2018-10-11

Family

ID=62025936

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/022093 Ceased WO2018169901A1 (fr) 2017-03-13 2018-03-13 Promoteurs synthétiques

Country Status (5)

Country Link
US (1) US11718860B2 (fr)
EP (1) EP3596221A1 (fr)
JP (1) JP2020509772A (fr)
CN (1) CN110582574A (fr)
WO (1) WO2018169901A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115552019A (zh) * 2020-05-27 2022-12-30 苏黎世大学 在髓样细胞和小胶质细胞中特异性表达治疗性蛋白的病毒载体
WO2024182378A1 (fr) * 2023-02-27 2024-09-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Procédés et matériels pour le traitement du syndrome de prader-willi
WO2024189614A1 (fr) * 2023-03-12 2024-09-19 Circuit Bio Ltd. Promoteurs synthétiques spécifiques de tissu et circuits et utilisation de ceux-ci
WO2024236504A1 (fr) * 2023-05-15 2024-11-21 Takeda Pharmaceutical Company Limited Séquences et procédés d'administration d'adn et d'arn
WO2024243460A1 (fr) * 2023-05-23 2024-11-28 Abintus Bio, Inc. Vecteurs et procédés de transduction in vivo
WO2025029678A2 (fr) * 2023-07-28 2025-02-06 Dana-Farber Cancer Institute, Inc. Promoteurs synthétiques, unités transcriptionnelles, vecteurs et compositions pharmaceutiques à spécificité améliorée de cellules cancéreuses ovariennes et méthodes
WO2025080988A1 (fr) * 2023-10-13 2025-04-17 Senti Biosciences, Inc. Éléments régulateurs modifiés
WO2025196762A1 (fr) 2024-03-22 2025-09-25 Meatologic Ltd Molécules synthétiques d'acide nucléique détectant des conditions cellulaires et/ou environnementales, pour fournir de manière autonome un phénotype cellulaire souhaité, cellules, produits et leurs utilisations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
DE19831420A1 (de) * 1998-07-14 2000-01-20 Hoechst Marion Roussel De Gmbh Expressionssysteme enthaltend chimäre Promotoren mit Bindungsstellen für rekombinante Transkriptionsfaktoren
WO2009007980A1 (fr) 2007-07-11 2009-01-15 Yeda Research And Development Co. Ltd. Systèmes de produits de construction d'acide nucléique pouvant diagnostiquer ou traiter un état cellulaire
MX2016006816A (es) * 2013-11-29 2016-08-19 Ucb Biopharma Sprl Promotores sinteticos para celulas de ovario de hamster chino (cho), metodos de produccion de promotores sinteticos usando modulos de sitio de union del factor de transcripcion.
EP3981438A1 (fr) 2015-05-04 2022-04-13 The Brigham and Women's Hospital, Inc. Vecteur hsv1 oncolytique et procédés d'utilisation
EP3310915A4 (fr) 2015-06-19 2019-04-10 Massachusetts Institute of Technology Immunothérapie tumorale

Also Published As

Publication number Publication date
US20210171977A1 (en) 2021-06-10
EP3596221A1 (fr) 2020-01-22
JP2020509772A (ja) 2020-04-02
US11718860B2 (en) 2023-08-08
CN110582574A (zh) 2019-12-17
WO2018169901A1 (fr) 2018-09-20

Similar Documents

Publication Publication Date Title
WO2018169901A8 (fr) Promoteurs synthétiques
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
PH12019502875A1 (en) Antibody molecules to cd73 and uses thereof
WO2018195439A3 (fr) Modulateurs de k-ras
EP4403229A3 (fr) Expression de pten-long avec des virus oncolytiques
WO2019108733A3 (fr) Anticorps cd47 et leurs utilisations dans le traitement du cancer
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
EP4219559A3 (fr) Anticorps pour lilrb2
WO2018064119A8 (fr) Modulateurs de calpain et leurs utilisations thérapeutiques
EP4545544A3 (fr) Arn crispr modifié et arn crispr unique modifié et leurs utilisations
WO2017031458A3 (fr) Conjugués anticorps-médicaments anti-dll3 et méthodes d'utilisation
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
HK1254728A1 (zh) 用於癌症免疫疗法的nkg2d-ig融合蛋白
WO2015151080A3 (fr) Conjugaison spécifique d'une molécule de liaison cellulaire
MX2019007021A (es) Anticuerpos il-11ra.
EP4488286A3 (fr) Compositions de conjugués saccharide-polypeptide et leurs procédés d'utilisation
EP4527466A3 (fr) Récepteurs antigéniques chimériques anti-dll3 et leurs utilisations
WO2021055577A3 (fr) Anticorps anti-klk7, anticorps anti-klk5, anticorps multispécifiques anti-klk5/klk7, et leurs procédés d'utilisation
WO2018069871A3 (fr) Protéines de liaison anti-kras
AU2019321490A8 (en) Ox40-binding polypeptides and uses thereof
WO2020055643A3 (fr) Composés, compositions et méthodes de traitement ou de prévention de cancers induits par her
EP3242688A4 (fr) Conjugués contenant du platine et ciblant cox-2, et utilisation de ces derniers dans le traitement de tumeurs et de cancers
WO2018187372A3 (fr) Dispositifs et systèmes microfluidiques de diffusion et leurs procédés de fabrication et d'utilisation
PH12020551543A1 (en) Therapeutic modulators of the reverse mode of atp synthase
WO2020028269A3 (fr) Molécules multispécifiques de liaison aux treg

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18718955

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019550749

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018718955

Country of ref document: EP

Effective date: 20191014